JP2020525498A5 - - Google Patents

Download PDF

Info

Publication number
JP2020525498A5
JP2020525498A5 JP2019572377A JP2019572377A JP2020525498A5 JP 2020525498 A5 JP2020525498 A5 JP 2020525498A5 JP 2019572377 A JP2019572377 A JP 2019572377A JP 2019572377 A JP2019572377 A JP 2019572377A JP 2020525498 A5 JP2020525498 A5 JP 2020525498A5
Authority
JP
Japan
Prior art keywords
fusion protein
use according
per year
seq
fix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019572377A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020525498A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/067523 external-priority patent/WO2019002532A1/en
Publication of JP2020525498A publication Critical patent/JP2020525498A/ja
Publication of JP2020525498A5 publication Critical patent/JP2020525498A5/ja
Pending legal-status Critical Current

Links

JP2019572377A 2017-06-29 2018-06-29 血友病の予防的処置のための第ix因子およびヒトアルブミンを含む融合タンパク質に関する21日の投与計画およびその方法 Pending JP2020525498A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762526377P 2017-06-29 2017-06-29
US62/526,377 2017-06-29
PCT/EP2018/067523 WO2019002532A1 (en) 2017-06-29 2018-06-29 21-DAY FUSION PROTEIN DRAFTING COMPRISING IX FACTOR AND HUMAN ALBUMIN FOR THE PROPHYLACTIC TREATMENT OF HEMOPHILIA AND ASSOCIATED METHODS

Publications (2)

Publication Number Publication Date
JP2020525498A JP2020525498A (ja) 2020-08-27
JP2020525498A5 true JP2020525498A5 (enExample) 2021-07-26

Family

ID=62815032

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019572377A Pending JP2020525498A (ja) 2017-06-29 2018-06-29 血友病の予防的処置のための第ix因子およびヒトアルブミンを含む融合タンパク質に関する21日の投与計画およびその方法

Country Status (15)

Country Link
US (1) US20200115436A1 (enExample)
EP (1) EP3645034B1 (enExample)
JP (1) JP2020525498A (enExample)
KR (1) KR102597725B1 (enExample)
CN (1) CN110799209A (enExample)
AU (1) AU2018294517B2 (enExample)
CA (1) CA3068360A1 (enExample)
DK (1) DK3645034T5 (enExample)
ES (1) ES2963665T3 (enExample)
IL (1) IL271160B2 (enExample)
MX (1) MX2019014651A (enExample)
PL (1) PL3645034T3 (enExample)
RU (1) RU2020103424A (enExample)
SG (1) SG10202111032PA (enExample)
WO (1) WO2019002532A1 (enExample)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2405550A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
US7939632B2 (en) 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
CA2770609A1 (en) * 2009-08-20 2011-02-24 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
CN103140237A (zh) 2010-07-09 2013-06-05 比奥根艾迪克依蒙菲利亚公司 因子ix多肽及其使用方法
TW201427685A (zh) * 2012-09-25 2014-07-16 Biogen Idec Inc Fix多肽的應用
CA2934081A1 (en) * 2013-12-23 2015-07-02 Csl Limited Fusion proteins comprising factor ix for prophylactic treatment of hemophilia and methods thereof
KR20160143820A (ko) * 2014-04-11 2016-12-14 시에스엘 리미티드 출혈의 예방 및 치료를 위한 반감기 연장 인자 fviia 단백질 및 이의 투약 용법

Similar Documents

Publication Publication Date Title
Mannucci Hemophilia treatment innovation: 50 years of progress and more to come
CN103917554B (zh) 用于改善重构后纯化的因子viii的稳定性的方法
EP2125004B1 (en) Synergistic therapeutic use of prothrombin complex concentrates with fviii concentrates
ES2392569T3 (es) Uso de preparaciones FVIII estabilizadas VWF para administración extravascular en la terapia y el tratamiento profiláctico de trastornos de hemorragias
TWI690325B (zh) 因子viii多肽調配物
JP2018522563A5 (enExample)
JP2017521074A5 (enExample)
RU2016129911A (ru) Слитые белки, содержащие фактор ix, для профилактического лечения больных гемофилией и способы его осуществления
JP2020525498A5 (enExample)
Schulte Challenges for new haemophilia products from a manufacturer’s perspective
US11554156B2 (en) Pharmaceutical formulations of C1 esterase inhibitor
CN112218622A (zh) 包含核壳结构的微粒作为活性成分的用于增加凝血因子基因表达的组合物
JP2019524089A5 (enExample)
Escobar Treatment on demand–in vivo dose finding studies
Goubran et al. New monoclonal/bi-specific antibodies: reshaping transfusion medicine beyond replacement
RU2020103424A (ru) Схема введения с 21-дневными интервалами слитых белков, содержащих фактор ix и альбумин человека, для профилактического лечения гемофилии и способы такого лечения
US20200289624A1 (en) Methods and compositions related to long half-life coagulation complexes
US7977460B2 (en) Compositions comprising coagulation factors IXA and VIII for the treatment of haemophilia A or B
Feistritzer et al. Successful immune tolerance induction using turoctocog alfa in an adult haemophilia A patient
AU2015245941A1 (en) Half-life extended Factor FVIIa protein for prevention and treatment of bleeding and dosing regimens therefor
Тарасова Innonafactor: The first Russian recombinant factor IX
Kuznar Investigational Small Molecule Rapidly Reverses Effects of New Oral Anticoagulants, Heparins.
HK40027732B (en) 21-day dosing regimen for fusion proteins comprising factor ix and human albumin for prophylactic treatment of hemophilia and methods thereof